NICE final draft guidance supports use of ranibizumab for diabetic macular oedema

Source: NICE
Area: News
In its Final Appraisal Determination, NICE is supporting the use of ranibizumab as an option for treating visual impairment caused by diabetic macular oedema (DMO). NICE conducted a rapid review of the original guidance, published in November 2011, because the manufacturer submitted a revised Patient Access Scheme, together with updated analyses showing the drug's superior relative effect among a sub-group of people with DMO.   The draft guidance states that ranibizumab is now recommended as an option for treating visual impairment due to diabetic macular oedema (Read more...)

Full Story →